Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Zura Bio Ltd ZURA

Healthcare Biotechnology
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ZURA)

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

Business Wire 6 hours ago

Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Business Wire 7 days ago

Zura Bio to Participate in Two Upcoming Investor Conferences in November

Business Wire October 30, 2024

Zura Bio to Present at Three Upcoming Investor Conferences in September

Business Wire September 3, 2024

Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Business Wire August 13, 2024

Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants

Business Wire August 12, 2024

Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants

Business Wire August 9, 2024

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

GlobeNewswire August 1, 2024

Zura Bio Commences Warrant Exchange Offer and Consent Solicitation

Business Wire July 12, 2024
View More News ››

Opinion & Analysis (NDAQ:ZURA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ZURA)

ZURA ...... You're rich !!!!!!

Ka f'king booom
Iseneschal - March 22, 2023
View more Bullboard ››

Trillion Energy International Inc.

Trillion Energy International Inc.

Trillion Energy International Inc. is a Canada-based oil and gas producing company that strives to maximize shareholder value ...
View More »